N. Engl. J. Med. 381, 2209–2218 (2019)
A conjugate vaccine for typhoid is immunogenic in children in a region in which typhoid is endemic.
Typhoid fever is a systemic febrile illness that disproportionately affects children and teenagers and is a major public-health challenge in low- and middle-income countries. Although two vaccines are currently available, vaccination has not been widely implemented due to low immunogenicity and challenges in delivery to young children.
A typhoid conjugate vaccine (TCV) has recently been developed with the intention of improving immunogenicity relative to that of previous vaccines. In a phase 3 trial in Kathmandu, Nepal, where typhoid is a major problem, 20,019 children were randomly assigned to receive TCV or the MenA vaccine. A single dose of the TCV was immunogenic and was effective in reducing Salmonella Typhi bacteremia.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Stower, H. A conjugate vaccine for typhoid. Nat Med 26, 21 (2020). https://doi.org/10.1038/s41591-019-0743-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-019-0743-5